FDA to Sharply Restrict Use of Two Monoclonal Antibody Treatments

The Food and Drug Administration will sharply restrict the use of two monoclonal antibody treatments according to a new report by the Washington Post.

According to WaPo, the Biden Administration is expected to halt distribution of monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly because they are 'ineffective against Omicron.

The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the covid-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.

"We want to make sure that patients get treatments that are effective, not treatments that don't work," said one of the officials, who spoke on the condition of anonymity to describe internal discussions.

The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies.

Biden administration officials noted that several therapies remain effective against omicron, including sotrovimab - a monoclonal antibody made by GlaxoSmithKline and Vir Biotechnology - and antiviral pills by Pfizer and by Merck and its partner, Ridgeback Biotherapeutics.

Ivermectin, HCQ, and life-saving monoclonal antibody treatments are going to be restricted while ineffective Covid vaccines and anti-viral pills made by Pfizer are distributed.

https://www.thegatewaypundit.com/2022/01/fda-sharply-restrict-use-two-monoclonal-antibody-treatments/